These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 21537159)

  • 1. Add-on rosiglitazone therapy improves plasminogen activity and high-density lipoprotein cholesterol in type 2 diabetes mellitus.
    Mustaffa N; Ibrahim S; Abdullah WZ; Yusof Z
    Blood Coagul Fibrinolysis; 2011 Sep; 22(6):512-20. PubMed ID: 21537159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Gaddi A; Ciccarelli L; Piccinni MN; Salvadeo SA; Pricolo F; Ferrari I; Gravina A; Ragonesi PD
    Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
    Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
    Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Study of Effects of Pioglitazone and Rosiglitazone on Various Parameters in Patients of Type-2 Diabetes Mellitus with Special Reference to Lipid Profile.
    Sharma SK; Verma SH
    J Assoc Physicians India; 2016 Sep; 64(9):24-28. PubMed ID: 27762511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peroxisome proliferator-activated receptor-gamma agonist increases both low-density lipoprotein cholesterol particle size and small high-density lipoprotein cholesterol in patients with type 2 diabetes independent of diabetic control.
    Bavirti S; Ghanaat F; Tayek JA
    Endocr Pract; 2003; 9(6):487-93. PubMed ID: 14715475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
    Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
    J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The long-term effects of rosiglitazone on serum lipid concentrations and body weight.
    Shim WS; Do MY; Kim SK; Kim HJ; Hur KY; Kang ES; Ahn CW; Lim SK; Lee HC; Cha BS
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):453-9. PubMed ID: 16984237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of metformin or rosiglitazone on serum concentrations of homocysteine, folate, and vitamin B12 in patients with type 2 diabetes mellitus.
    Sahin M; Tutuncu NB; Ertugrul D; Tanaci N; Guvener ND
    J Diabetes Complications; 2007; 21(2):118-23. PubMed ID: 17331860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2 diabetes.
    Berneis K; Rizzo M; Stettler C; Chappuis B; Braun M; Diem P; Christ ER
    Expert Opin Pharmacother; 2008 Feb; 9(3):343-9. PubMed ID: 18220486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of rosiglitazone on fasting and postprandial low- and high-density lipoproteins size and subclasses in type 2 diabetes.
    Rizzo M; Vekic J; Koulouris S; Zeljkovic A; Jelic-Ivanovic Z; Spasojevic-Kalimanovska V; Rini GB; Sakellariou D; Pastromas S; Mikhailidis DP; Manolis AS
    Angiology; 2010 Aug; 61(6):584-90. PubMed ID: 20462890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes.
    Hanefeld M; Patwardhan R; Jones NP;
    Nutr Metab Cardiovasc Dis; 2007 Jan; 17(1):13-23. PubMed ID: 17174222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK.
    Tilden DP; Mariz S; O'Bryan-Tear G; Bottomley J; Diamantopoulos A
    Pharmacoeconomics; 2007; 25(1):39-54. PubMed ID: 17192117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes.
    Phillips LS; Grunberger G; Miller E; Patwardhan R; Rappaport EB; Salzman A;
    Diabetes Care; 2001 Feb; 24(2):308-15. PubMed ID: 11213884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.
    Patel J; Anderson RJ; Rappaport EB
    Diabetes Obes Metab; 1999 May; 1(3):165-72. PubMed ID: 11220295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors.
    Chiquette E; Ramirez G; Defronzo R
    Arch Intern Med; 2004 Oct; 164(19):2097-104. PubMed ID: 15505122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.
    Wolffenbuttel BH; Gomis R; Squatrito S; Jones NP; Patwardhan RN
    Diabet Med; 2000 Jan; 17(1):40-7. PubMed ID: 10691158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
    Rosenstock J; Sugimoto D; Strange P; Stewart JA; Soltes-Rak E; Dailey G
    Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial.
    Lewin AJ; Kipnes MS; Meneghini LF; Plotkin DJ; Perevozskaya IT; Shah S; Maccubbin DL; Mitchel YB; Tobert JA;
    Clin Ther; 2004 Mar; 26(3):379-89. PubMed ID: 15110130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity.
    Yosefy C; Magen E; Kiselevich A; Priluk R; London D; Volchek L; Viskoper RJ
    J Cardiovasc Pharmacol; 2004 Aug; 44(2):215-22. PubMed ID: 15243303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Roberts VL; Stewart J; Issa M; Lake B; Melis R
    Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.